FILE:CELG/CELG-8K-20050913160330.txt.gz
EVENTS:	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Other Events
ITEM: Financial Statements and Exhibits
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 13, 2005 CELGENE CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-16132 22-2711928 - -------------------------------------------------------------------------------- (State or other jurisdiction of (Commission File Number) (IRS Employer incorporation) Identification No.) 86 Morris Avenue, Summit, New Jersey 07901 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (908) 673-9000 -------------------------------------------------------------------------- (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On September 13, 2005, Celgene Corporation announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) has posted on its website a briefing document for the ODAC meeting scheduled to review the REVLIMID (lenalidomide) New Drug Application (NDA) seeking approval for REVLIMID for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Attached hereto and incorporated by reference as Exhibit 99.1 is the Press Release announcing such information. ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. (c) Exhibit 99.1 - Press Release dated September 13, 2005. SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELGENE CORPORATION Date: September 13, 2005 By: /s/ Robert J. Hugin ---------------------------------------- Name: Robert J. Hugin Title: Senior Vice President and Chief Financial Officer

Exhibit 99.1 Contact: Robert J. Hugin Brian P. Gill Senior VP and CFO Director PR/IR Celgene Corporation Celgene Corporation (908) 673-9000 (908) 673-9000 FDA BRIEFING DOCUMENTS FOR ADVISORY COMMITTEE MEETING AVAILABLE ONLINE WASHINGTON, Sept 13, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the ODAC meeting scheduled to review the REVLIMID(R) (lenalidomide) New Drug Application (NDA) seeking approval for REVLIMID for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. In order to obtain access to the FDA and Celgene REVLIMID briefing documents, go to http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4174B2_01_01-Celgene- Revlimid.pdf. The ODAC meeting is scheduled from 8:00 a.m. EDT to 12:30 p.m. EDT on Wednesday, September 14, 2005. The NDA for REVLIMID is under FDA priority review with a PDUFA date of October 7, 2005. ABOUT CELGENE Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com. THIS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS WHICH ARE SUBJECT TO KNOWN AND UNKNOWN RISKS, DELAYS, UNCERTAINTIES AND OTHER FACTORS NOT UNDER THE COMPANY'S CONTROL, WHICH MAY CAUSE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM THE RESULTS, PERFORMANCE OR OTHER EXPECTATIONS EXPRESSED OR IMPLIED BY THESE FORWARD-LOOKING STATEMENTS. THESE FACTORS INCLUDE RESULTS OF CURRENT OR PENDING RESEARCH AND DEVELOPMENT ACTIVITIES, ACTIONS BY THE FDA AND OTHER REGULATORY AUTHORITIES, AND OTHER FACTORS DESCRIBED IN THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION SUCH AS OUR 10K, 10Q AND 8K REPORTS. # # #


